It is modified to selectively replicate in p16/Rb-defective cells, which include most human cancer cells.
The therapeutic potential of oncolytic virotherapy is not a simple consequence of the cytopathic effect but strongly relies on the induction of an endogenous immune response against transformed cells [REF].